SANTA CLARA (dpa-AFX) - Immutep Limited (IMMP,IMM.AX) said that it has
reached a clinical trial collaboration and supply agreement with Merck & Co.,
Inc. (MRK) to evaluate eftilagimod alfa (efti) in combination with Merck's
anti-PD-1 therapy, Keytruda (pembrolizumab) and chemotherapy for the first-line
treatment of metastatic non-small cell lung cancer or NSCLC in a pivotal Phase
III trial.

The collaboration follows two previous collaborations for the TACTI-002 Phase II
and TACTI-003 Phase IIb trials, which collectively treated over 350 patients.

As per the terms of the agreement, Immutep will conduct the registrational
TACTI-004 study and Merck will supply Keytruda. The agreement enables Immutep
and Merck to seek marketing authorization of the combination and to market their
respective compounds with a relevant label indication.

The companies retain the commercial rights to their respective compounds and are
free to conduct other clinical studies, either individually or in combination,
in any therapeutic area.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX